Pictet Asset Management Holding SA Has $158.01 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Pictet Asset Management Holding SA grew its position in Illumina, Inc. (NASDAQ:ILMN) by 245.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,182,454 shares of the life sciences company’s stock after purchasing an additional 840,423 shares during the period. Pictet Asset Management Holding SA owned approximately 0.75% of Illumina worth $158,011,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Cerity Partners LLC increased its stake in Illumina by 172.2% in the 3rd quarter. Cerity Partners LLC now owns 24,076 shares of the life sciences company’s stock valued at $3,140,000 after buying an additional 15,231 shares during the last quarter. Private Trust Co. NA grew its holdings in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 212 shares in the last quarter. Bank of Montreal Can increased its position in shares of Illumina by 6.1% in the third quarter. Bank of Montreal Can now owns 151,254 shares of the life sciences company’s stock valued at $19,681,000 after acquiring an additional 8,730 shares during the last quarter. FMR LLC raised its holdings in Illumina by 127.3% during the third quarter. FMR LLC now owns 767,294 shares of the life sciences company’s stock worth $100,063,000 after acquiring an additional 429,723 shares in the last quarter. Finally, Brooklyn Investment Group acquired a new position in Illumina during the third quarter valued at approximately $66,000. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and lowered their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Piper Sandler increased their price target on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Guggenheim lowered their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Citigroup cut their target price on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $140.90.

Illumina Price Performance

NASDAQ:ILMN opened at $80.00 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a market cap of $12.67 billion, a price-to-earnings ratio of -10.42, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52 week low of $79.30 and a 52 week high of $156.66. The firm’s 50-day simple moving average is $102.80 and its 200 day simple moving average is $126.79.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.